Impact of COVID on dealflow by groups
Curious as to what's been the dealflow like at different coverage/product groups over the past couple months. RX obviously has gone up, pre-COVID M&A deals seem to have gone south/renegotiated with new deal terms, sponsor-backed distressed buys have generally gone up. What are other trends people are seeing rn?
Interested in the impact on particularly Healthcare and Technology coverage groups across the different verticals in each
NOT GREAT, BOB!
Both DCM & ECM are up http://graphics.wsj.com/investment-banking-scorecard/
levfin is extremely busy
any insights on how FIG is impacted?
Seeing m&a pick up a ton over the last month. Looking like a jam packed 2H2020
what coverage?
Industrials and consumer
How does DCM look?
https://markets.ft.com/data/league-tables/tables-and-trends/Bonds
How about Industrials?
any insight on consumer or healthcare
Ex hic quia voluptatem commodi ratione ut consequatur. Delectus quos blanditiis amet expedita labore perferendis aspernatur. Tenetur sequi ipsam corporis consectetur labore qui rerum maiores.
Possimus fugiat in et perspiciatis. Vel voluptatem saepe delectus qui recusandae eius. Ratione voluptatum et alias a ex hic. Maxime voluptatem accusamus quibusdam reiciendis. Quidem officiis saepe similique minima sed ut.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...